

IWAKI SEIYAKU Co., Ltd.

Announcement on equity investment to KinoPharma, Inc.

IWAKI SEIYAKU CO., LTD. (IWAKI) announced the equity investment through the third-party allocation of new shares of KinoPharma, Inc. (KinoPharma).

IWAKI and KinoPharma jointly developed the ointment with anti-HPV agent founded by KinoPharma. After IWAKI successfully founded the ointment formulation to meet the target profile, KinoPharma confirmed its safety profile for human use. Then IWAKI and KinoPharma have entered into the co-development and commercialization agreement in order to conduct clinical development with this ointment for the treatment of warts caused by HPV. Based on this agreement, IWAKI proceeded this equity investment.

KinoPharma is a clinical stage biopharma to research and develop small-molecule drugs based on new concept in areas of high medical needs, such as antiviral drugs, and provide them to patients around the world who are waiting for them as quickly as possible. Its leading program is in the Phase 2 clinical trial for the treatment of cervical intraepithelial neoplasia (CIN) in Japan and South Korea.

IWAKI is a pharmaceutical company focused on manufacturing and distribution of the ethical and OTC drugs. The company is especially active in the market of medical care for dermatology. IWAKI expands its brand and product portfolio in the future and will make all the efforts to supply this product stably.

Contact:

Corporate Strategy Division, IWAKI SEIYAKU Co., Ltd.

E-mail : iyakukaihatsu2011@iwakiseiyaku.co.jp

HP : https://www.iwakiseiyaku.co.jp/en/contact_list/licensing_form.html